Primary sclerosing cholangitis Market Synopsis:
Primary sclerosing cholangitis Market Size Was Valued at USD 142.1 Million in 2023, and is Projected to Reach USD 180.6 Million by 2032, Growing at a CAGR of 2.7% From 2024-2032.
Primary sclerosing cholangitis (PSC) is a primary, principally cholangiographic, and relentlessly progressive liver disease that results from inflammation and fibrosis of the bile ducts with associated impairment of liver function and liver cirrhosis. This condition then leads to cholestasis and then liver failure, portal hypertension and increased incidence of Liver cancer. It is not still known how PSC actually develops, but its relations to the immune system and other disorders such as IBD are common. PSC is a diseases, which mainly impacts middle aged men, and to this day there is no cure for it. Here management aims at reducing the severity of the symptoms and reduce the rate at which the diseases progress.
The main factors that are pushing the growth of the global primary sclerosing cholangitis market include the increasing rate of incidence of liver diseases, increasing awareness of rare liver diseases, and progress in diagnostic approaches. Even so, there has been a increase in cases of related diseases such as autoimmune diseases and inflammatory bowel diseases which has led to more its sister disease, PSC. This market is reinforced with advances made in liver function tests, imaging platforms and biopsy methods that enable early detection and effective control of this ailment. The goal of the current treatment is not a cure, but symptom management, prevention of bile duct infections and the slowing of the progression of liver damage.
The market for primary sclerosing cholangitis remains active due to constant advancements in research and developable studies in liver disease and medical evaluation of liver transplants as a treatment for PSC. Several new molecular entities and biologics targeting the immune system and newer formulations of the current drugs and therapies may provide improved control over the disease. Governments and pharmaceutical businesses also focus more on the research on rare diseases, which is also boosting the market growth. The lack of clear treatment and focus on patient enhancement is providing much unmet need for this market to grow.
.webp)
Primary sclerosing cholangitis Market Trend Analysis:
Increasing Focus on Novel Therapeutics
- Owing to the progressive nature of primary sclerosing cholangitis, the existing treatment options are limited, and there is a trend of seeking new therapeutic molecules. Currently, the pharmaceutical companies, and the research institutions are striving to develop tailored approaches to dealing with PSC origins. This comprises immune-modifying agents as well as biologic products with a role in modulation of immunity and minimisation of inflammation of bile ducts. Another area of research is in pursuit of antifibrotic drugs, which may be used to treat or at least halt further development of liver fibrosis. Furthermore, liver transplantation is considered as the only cure for advanced PSC and development of effective treatments such as new advancements in the transplant technology and management shall enhance the life quality of the patient and boost the market in turn.
Advancements in Diagnostic Tools
- Thus, one of the marketing opportunities of the primary sclerosing cholangitis is the development of diagnostics. Emerging technologies, as well as, advances in imaging technologies like MRCP and patient-oriented biomarkers, allow for elevating the diagnostic accuracy for PSC. Because Parkinson’s is a progressive condition, early diagnosis is highly desirable and may improve the situation by slowing the decline in liver function. Moreover the development of fresh genetic and individualized approaches such as targeted treatments due to improved genetic sequencing are also emerging. Those firms that are willing to invest in diagnostics technologies & genetic research will likely reap from the growing trend of the PSC market for better quality and non-invasive diagnostic tools.
Primary sclerosing cholangitis Market Segment Analysis:
Primary sclerosing cholangitis Market is Segmented on the basis of Drug Class, Route of Administration, and Region.
By Drug Class, Ursodeoxycholic acid (UDCA) segment is expected to dominate the market during the forecast period
- The segment for Ursodeoxycholic acid (UDCA) is anticipated to reign supreme in the market for primary sclerosing cholangitis in the forecast period. UDCA is the first line treatment for this disease despite the controversy of its effectiveness for managing PSC. It achieves this by increasing the flow of bile and at the same time decreasing the toxicity of the bile that is often felt when one has itching and slows the rate at which the liver disease worsens. Despite the fact that UDCA serves as nothing more than a supportive care, its importance in the treatment of PSC is undisputed due to the extensive role of the drug in alleviating symptoms in the patient. Further investigation of UDCA and other drugs including immunosuppressive and antifibrotic is also increasing its prominence in the market.
By Route of Administration, Oral segment expected to held the largest share
- The primary sclerosing cholangitis oral route of administration segment is expected to dominate this market due to the high demand. Oral administration is the common route in the management of PSC using drugs such as UDCA, and other bile acid therapies. They are also preferred due to the simplicity of administration to patients and their convenience especially to those patients living with chronic diseases which often need to be managed for long term. Thus, the development of new oral formulations that bring better results in bioavailability and fewer side effects is placing this segment in a position of advantage. In particular, the large share of the oral therapies market indicates the higher accessibility of such therapies for patients worldwide.
Primary sclerosing cholangitis Market Regional Insights:
North America is Expected to Dominate the Market Over the Forecast period
- Primary sclerosing cholangitis market was largest in North America in 2023. The primary factors propelling the market in the region include the high incidence rate of PSC especially in the U.S and a developed infrastructure of health care networks. North American Region has focused remarkably on the study of Rare Diseases, and additionally with the high capital investments by Pharmaceutical companies and research institutions the region gains high preferences. Essentially, diagnostic machinery and higher usage of innovative therapies too contribute significantly to the growth of the market. It is estimated that North America PSC market in 2023 would be around 40 % of the global market and U.S. dominate the market.
Active Key Players in the Primary sclerosing cholangitis Market:
- AbbVie Inc. (U.S.)
- Allergan PLC (Ireland)
- Astellas Pharma Inc. (Japan)
- Bayer AG (Germany)
- Bristol-Myers Squibb (U.S.)
- Dicerna Pharmaceuticals, Inc. (U.S.)
- Dr. Falk Pharma GmbH (Germany)
- Genfit SA (France)
- Gilead Sciences, Inc. (U.S.)
- GlaxoSmithKline PLC (U.K.)
- Intercept Pharmaceuticals, Inc. (U.S.)
- Novartis International AG (Switzerland)
- Pfizer Inc. (U.S.)
- Shire PLC (U.K.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Other Active Players
|
Primary sclerosing cholangitis Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 142.1 Million |
|
Forecast Period 2024-32 CAGR: |
2.7% |
Market Size in 2032: |
USD 180.6 Million |
|
Segments Covered: |
By Drug Class |
|
|
|
By Route of Administration |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Primary sclerosing cholangitis Market by Drug Class
4.1 Primary sclerosing cholangitis Market Snapshot and Growth Engine
4.2 Primary sclerosing cholangitis Market Overview
4.3 Ursodeoxycholic acid (UDCA)
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Ursodeoxycholic acid (UDCA): Geographic Segmentation Analysis
4.4 Corticosteroids
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Corticosteroids: Geographic Segmentation Analysis
4.5 Azathioprine
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Azathioprine: Geographic Segmentation Analysis
4.6 Mercaptopurine
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Mercaptopurine: Geographic Segmentation Analysis
4.7 Budesonide
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 Budesonide: Geographic Segmentation Analysis
4.8 Obeticholic acid
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.8.3 Key Market Trends, Growth Factors and Opportunities
4.8.4 Obeticholic acid: Geographic Segmentation Analysis
4.9 Monoclonal antibody
4.9.1 Introduction and Market Overview
4.9.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.9.3 Key Market Trends, Growth Factors and Opportunities
4.9.4 Monoclonal antibody: Geographic Segmentation Analysis
4.10 Others
4.10.1 Introduction and Market Overview
4.10.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.10.3 Key Market Trends, Growth Factors and Opportunities
4.10.4 Others: Geographic Segmentation Analysis
Chapter 5: Primary sclerosing cholangitis Market by Route of Administration
5.1 Primary sclerosing cholangitis Market Snapshot and Growth Engine
5.2 Primary sclerosing cholangitis Market Overview
5.3 Oral
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Oral: Geographic Segmentation Analysis
5.4 Parenteral
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Parenteral: Geographic Segmentation Analysis
5.5 Others
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Others: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Primary sclerosing cholangitis Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 ABBVIE INC. (U.S.)
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 ALLERGAN PLC (IRELAND)
6.4 ASTELLAS PHARMA INC. (JAPAN)
6.5 BAYER AG (GERMANY)
6.6 BRISTOL-MYERS SQUIBB (U.S.)
6.7 DICERNA PHARMACEUTICALS INC. (U.S.)
6.8 DR. FALK PHARMA GMBH (GERMANY)
6.9 GENFIT SA (FRANCE)
6.10 GILEAD SCIENCES INC. (U.S.)
6.11 GLAXOSMITHKLINE PLC (U.K.)
6.12 INTERCEPT PHARMACEUTICALS INC. (U.S.)
6.13 NOVARTIS INTERNATIONAL AG (SWITZERLAND)
6.14 PFIZER INC. (U.S.)
6.15 SHIRE PLC (U.K.)
6.16 TEVA PHARMACEUTICAL INDUSTRIES LTD. (ISRAEL)
6.17 OTHER ACTIVE PLAYERS
Chapter 7: Global Primary sclerosing cholangitis Market By Region
7.1 Overview
7.2. North America Primary sclerosing cholangitis Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Drug Class
7.2.4.1 Ursodeoxycholic acid (UDCA)
7.2.4.2 Corticosteroids
7.2.4.3 Azathioprine
7.2.4.4 Mercaptopurine
7.2.4.5 Budesonide
7.2.4.6 Obeticholic acid
7.2.4.7 Monoclonal antibody
7.2.4.8 Others
7.2.5 Historic and Forecasted Market Size By Route of Administration
7.2.5.1 Oral
7.2.5.2 Parenteral
7.2.5.3 Others
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Primary sclerosing cholangitis Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Drug Class
7.3.4.1 Ursodeoxycholic acid (UDCA)
7.3.4.2 Corticosteroids
7.3.4.3 Azathioprine
7.3.4.4 Mercaptopurine
7.3.4.5 Budesonide
7.3.4.6 Obeticholic acid
7.3.4.7 Monoclonal antibody
7.3.4.8 Others
7.3.5 Historic and Forecasted Market Size By Route of Administration
7.3.5.1 Oral
7.3.5.2 Parenteral
7.3.5.3 Others
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Russia
7.3.6.2 Bulgaria
7.3.6.3 The Czech Republic
7.3.6.4 Hungary
7.3.6.5 Poland
7.3.6.6 Romania
7.3.6.7 Rest of Eastern Europe
7.4. Western Europe Primary sclerosing cholangitis Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Drug Class
7.4.4.1 Ursodeoxycholic acid (UDCA)
7.4.4.2 Corticosteroids
7.4.4.3 Azathioprine
7.4.4.4 Mercaptopurine
7.4.4.5 Budesonide
7.4.4.6 Obeticholic acid
7.4.4.7 Monoclonal antibody
7.4.4.8 Others
7.4.5 Historic and Forecasted Market Size By Route of Administration
7.4.5.1 Oral
7.4.5.2 Parenteral
7.4.5.3 Others
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 The Netherlands
7.4.6.5 Italy
7.4.6.6 Spain
7.4.6.7 Rest of Western Europe
7.5. Asia Pacific Primary sclerosing cholangitis Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Drug Class
7.5.4.1 Ursodeoxycholic acid (UDCA)
7.5.4.2 Corticosteroids
7.5.4.3 Azathioprine
7.5.4.4 Mercaptopurine
7.5.4.5 Budesonide
7.5.4.6 Obeticholic acid
7.5.4.7 Monoclonal antibody
7.5.4.8 Others
7.5.5 Historic and Forecasted Market Size By Route of Administration
7.5.5.1 Oral
7.5.5.2 Parenteral
7.5.5.3 Others
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Primary sclerosing cholangitis Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Drug Class
7.6.4.1 Ursodeoxycholic acid (UDCA)
7.6.4.2 Corticosteroids
7.6.4.3 Azathioprine
7.6.4.4 Mercaptopurine
7.6.4.5 Budesonide
7.6.4.6 Obeticholic acid
7.6.4.7 Monoclonal antibody
7.6.4.8 Others
7.6.5 Historic and Forecasted Market Size By Route of Administration
7.6.5.1 Oral
7.6.5.2 Parenteral
7.6.5.3 Others
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkiye
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Primary sclerosing cholangitis Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Drug Class
7.7.4.1 Ursodeoxycholic acid (UDCA)
7.7.4.2 Corticosteroids
7.7.4.3 Azathioprine
7.7.4.4 Mercaptopurine
7.7.4.5 Budesonide
7.7.4.6 Obeticholic acid
7.7.4.7 Monoclonal antibody
7.7.4.8 Others
7.7.5 Historic and Forecasted Market Size By Route of Administration
7.7.5.1 Oral
7.7.5.2 Parenteral
7.7.5.3 Others
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
|
Primary sclerosing cholangitis Market |
|||
|
Base Year: |
2023 |
Forecast Period: |
2024-2032 |
|
Historical Data: |
2017 to 2023 |
Market Size in 2023: |
USD 142.1 Million |
|
Forecast Period 2024-32 CAGR: |
2.7% |
Market Size in 2032: |
USD 180.6 Million |
|
Segments Covered: |
By Drug Class |
|
|
|
By Route of Administration |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
